Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Rivaroxaban (Dexa Medica vs Xarelto) in Healthy Subjects
NCT06558058Phase 1Completed
- Sponsor
- Dexa Medica
- Start
- Jun 2023
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rivaroxaban in venous thromboembolism (VTE) (2 arms), sponsored by Dexa Medica. Primary endpoints: Area Under the Curve from time 0 to the last measurable concentration at 36 hours and Maximum Observed Plasma Concentration at 36 hours. Started Jun 2023; status: completed.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT06558058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06558058.